Lorin A. Ferris

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke et al. · Cancer Discovery · 2018 · 298 citations · Full text

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer

Justin F. Gainor, Diane Tseng, Satoshi Yoda et al. · JCO Precision Oncology · 2017 · 255 citations

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

Emily Chin, Beow Y. Yeap, Lorin A. Ferris et al. · Journal of Thoracic Oncology · 2018 · 139 citations · Full text

Hepatotoxicity Associated, Medicine, Immunology +8

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA

Ibiayi Dagogo‐Jack, A. Rose Brannon, Lorin A. Ferris et al. · JCO Precision Oncology · 2018 · 129 citations · Full text

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer

Lauren L. Ritterhouse, Siraj M. Ali, Mark Bailey et al. · Journal of Thoracic Oncology · 2017 · 127 citations · Full text

Other Oncogenic Drivers, Oncology, Oncogenic Agent +8